Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Palo Alto Networks has added another 8% this week to close at $419.91, pushing the one-month gain to 26% and pulling the options and short-positioning picture even further in the bulls' favour.
The options market, which last week's note flagged as unusually bullish, has held that tone without overextending. The put/call ratio is 0.864, a touch below the 20-day mean of 0.886 and roughly 0.7 standard deviations on the call side of average. That is less aggressive than the 0.85 reading from late September, suggesting the rally has taken some of the urgency out of call chasing rather than inflaming it further. The 52-week low PCR is 0.754, so the options market is bullish but not stretched. The borrow picture tells a similar story: availability is extremely loose at 5,630%, meaning shares available to borrow dwarf the short interest by a factor of more than 56. Borrowing costs have drifted up 5% on the week to 0.47% annually, still trivially cheap. Short interest has continued to ease, falling another 3.7% on the week to 2.84% of the free float. The combination of plentiful availability, low cost and shrinking short positions points to a lending market with no stress whatsoever.
The Street has moved constructively into the rally. TD Cowen raised its target to $440 from $400 this week, maintaining a Buy, while BTIG lifted to $425 from $404 last week. Morgan Stanley pushed its Overweight target to $410 from $394 on September 21. Most targets now cluster in the $400 to $450 range, and the consensus mean is $396.92, which the stock has now surpassed. The notable outlier remains Bernstein, which downgraded to Market Perform on September 17 and carries a $351 target, citing slowing core revenue growth and M&A risk. The bull case centres on the platformization momentum: a record 220 net new deals, 120% net revenue retention among platformized customers, and a path to $20 billion in next-generation security ARR by 2030. Bears point to core revenue growth decelerating from 14.1% to 13.0% between the last two quarters and the risk that one-year usage-based deals reduce earnings visibility. Valuation is not cheap: the price/earnings multiple has expanded roughly 20 points over the past 30 days to 89x, and EV/EBITDA now trades at 63x.
One institutional data point is worth noting. Vanguard's Schedule 13G/A filed in late March showed its stake falling to zero from a prior 9.75%, a large reduction. A separate Vanguard entity, Vanguard Capital Management, subsequently filed a 13G in April disclosing a 7.44% holding. The ORTEX 13D/G register shows no activist on the share register. Stakes are event-driven disclosures around the 5% threshold, and holders falling below 5% may exit without a further filing. BlackRock remains the largest disclosed holder at 9.26% as of September 30, having added 3.3 million shares in the quarter. JP Morgan Asset Management added 6.2 million shares in the same period, a meaningful increase.
Insider activity has been exclusively in the sell column. The CFO, Dipak Golechha, sold over $7 million in shares on September 24, all under pre-arranged 10b5-1 plans, which reduces the signal value. The net 90-day insider activity is roughly minus $21 million across all insiders. Planned sales under 10b5-1 arrangements reflect schedule rather than conviction, but the absence of any open-market buying is worth keeping in mind as the stock approaches all-time high territory.
The next earnings print is November 13. The most recent result, on September 1, sent the stock down 14% on the day and a further 12% over the following five sessions. PANW has since recovered all of that decline and added more. With the stock now trading above most analyst targets and at a PE of 89x, how the Street interprets the next data point on platformization deal flow and NGS ARR progression will be the central question at that release.
See the live data behind this article on ORTEX.
Open PANW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
